In the quiet suburbs of Arlington, Massachusetts, a two-story house serves as the headquarters for what may be the most significant shift in psychiatric treatment in half a century. The Accord clinic, founded by psychiatrist Matt Bernstein, is currently the only residential facility in the United States dedicated to "Metabolic Psychiatry"—a field that posits that mental disorders like schizophrenia and bipolar disorder are not merely "chemical imbalances" of the brain, but manifestations of metabolic dysfunction.
While the use of the ketogenic diet in medicine dates back over a century, its application as a primary intervention for severe mental illness is a radical departure from the standard of care. At Accord, the treatment is not merely an addition to a patient’s pill regimen; it is a "transformative" therapy designed to restore physical health and, crucially, provide a biological foundation for tapering off psychiatric medications.
Main Facts: The Emergence of Metabolic Psychiatry
The conceptual framework for the Accord clinic was popularized by Harvard-affiliated psychiatrist Chris Palmer in his 2022 book, Brain Energy. Palmer argued that mental disorders are essentially "metabolic disorders of the brain." By shifting the body’s fuel source from glucose to ketones, Palmer suggested that patients could achieve a remission of symptoms that medications often fail to provide.
The Accord clinic represents the first real-world test of this theory in a residential setting. Backed by a $600,000 research grant, the clinic is tracking patient outcomes over an 18-month period. Unlike traditional academic studies, Accord’s protocol explicitly includes support for drug tapering.
Two Futures for Psychiatry
The field currently stands at a crossroads between two distinct models:
- The Adjunctive Model: The ketogenic diet is used as a "supplement" to help manage the weight gain and metabolic side effects caused by antipsychotics. This model preserves the status quo of lifelong medication.
- The Transformative Model: The diet is viewed as a restorative therapy that fixes the underlying mitochondrial dysfunction. In this view, psychiatric drugs are seen as agents that may actually worsen metabolic health, and the ultimate goal is a medication-free or low-medication future.
Chronology: From Epilepsy to "Brain Energy"
The journey of the ketogenic diet from a niche pediatric treatment to a psychiatric intervention spans over a century of medical history and recent high-profile success stories.
- 1921: The ketogenic diet is first developed at the Mayo Clinic as a treatment for drug-resistant epilepsy. It was found that a high-fat, low-carbohydrate diet mimics the metabolic state of fasting, which stabilizes electrical activity in the brain.
- 2017–2019: Dr. Chris Palmer publishes a series of case reports in peer-reviewed journals detailing "miraculous" recoveries. One 2017 report described two patients with schizoaffective disorder; one successfully withdrew from all psychiatric drugs, while the other significantly reduced their dosage.
- 2021: The "Baszucki Story" goes public. Matt Baszucki, son of Roblox founder David Baszucki, recovers from treatment-resistant bipolar disorder after five years of failed interventions and 29 different medications. Under Palmer’s guidance, a ketogenic diet leads to his full functional recovery.
- 2022: Publication of Brain Energy. The book provides the biological "missing link," explaining how mitochondrial health dictates mental health.
- July 2024: The Accord clinic opens its doors in Arlington, MA, combining the dietary protocol with a "treatment without walls" philosophy.
Supporting Data: Comparing Clinical Outcomes
While anecdotal evidence is compelling, the "evidence base" for metabolic psychiatry is still being built. Current research suggests a strong correlation between metabolic health and psychiatric symptom reduction, particularly when medication tapering is involved.
The French vs. Stanford Cohort Studies
Two major cohort studies provide a rudimentary comparison of how tapering affects outcomes:
- The French Study (2022): 28 patients with severe mental illness were treated with a keto diet in a hospital setting. Two-thirds of the patients (18 out of 28) decreased their psychiatric medications during the study. The result was a 60% improvement in Clinical Global Impression (CGI-S) scores.
- The Stanford Study (2024): 21 patients with bipolar or schizophrenia were treated with a keto diet as a "supplemental" treatment. Most patients remained on their baseline medications. The result was a 31% improvement in CGI-S scores.
The data indicates that clinical improvement was nearly twice as great in the cohort where patients were encouraged to reduce their medication load, suggesting that the drugs themselves may interfere with the metabolic benefits of the diet.
Randomized Clinical Trials (RCTs)
The gold standard of research is beginning to catch up. A 2026 UK study of 88 patients with treatment-resistant depression compared the ketogenic diet to a "phytochemical" (plant-based) diet. While both groups improved significantly over six weeks, the keto group showed a slight edge in symptom reduction. However, the study highlighted a major hurdle: sustainability. Only 20% of the keto group adhered to the diet after the six-week active support period ended.
The Biological Rationale
Accord founder Matt Bernstein explains that the diet works by switching the brain’s fuel system. "Our modern diets rely on carbohydrates to produce glucose… but a ketogenic diet switches on a second method—burning fat—for fueling the mitochondria," Bernstein says.
- ATP Production: Ketones are a more efficient fuel for the mitochondria, the "powerhouses" of the cell.
- Mitophagy: The diet promotes the removal of damaged mitochondria.
- BDNF: Ketosis increases Brain-Derived Neurotrophic Factor (BDNF), a protein that promotes neuronal growth and flexibility.
Official Responses: The Politics of Tapering
Despite the promising data, the broader psychiatric establishment remains cautious. Matt Bernstein notes that there is a significant "political" and "liability" barrier to including tapering in formal academic research.
"Academic researchers cannot easily design studies that include medication tapering as a protocol element," Bernstein explains. "The liability exposure is significant, and IRB [Institutional Review Board] approval becomes complicated."
Furthermore, metabolic psychiatry is currently fighting for legitimacy within a field dominated by the pharmacological model. Proponents often hesitate to publicly advocate for tapering to avoid being labeled as "anti-medication," which could threaten the field’s credibility before a sufficient evidence base is established.
However, the staff at Accord—including nutritionists and social workers—argues that the standard pharmacological approach is failing. "We’re prescribing things that cause people to gain 80 pounds and become diabetic and die 15 to 20 years early," Bernstein says. Accord’s mission is to prove that there is a safer, more sustainable path.
Implications: Patient Accounts and the Question of Sustainability
The true test of metabolic psychiatry lies in the lives of the patients. At Accord, the results are often life-changing, though the path is not easy.
Case Study: Jack Grady
Jack Grady spent eight years in what his mother calls "hell." Diagnosed with bipolar 1 and plagued by voices, Jack was placed on a heavy cocktail of drugs, including clozapine, the "last resort" for psychosis. "I was a zombie," Jack recalls. "I was sedated, not motivated… I just always wanted to sleep."
After two months at Accord and a subsequent tapering process at home, Jack’s voices have nearly vanished. "It was like a light switch changed," his mother says. Today, Jack is working, making music, and exercising—behaviors that were impossible under heavy sedation.
Case Study: Meredith Marks
Meredith Marks lived with psychiatric diagnoses for 27 years, undergoing 36 sessions of electroconvulsive therapy (ECT) and taking a seven-drug cocktail. Within a month of starting the keto diet at Accord, she felt a "ridiculous" boost in energy. She has since reduced her medication from seven drugs to five and has not had a manic or depressive episode in a year. "Now I am really genuinely, authentically me," she says.
The Sustainability Challenge
The primary criticism of the ketogenic diet is that it is too restrictive to maintain. To combat this, Accord employs health coaches like Donika Hristova, who used the diet to recover from bipolar 2 herself.
The clinic’s 18-month follow-up study will be crucial in answering whether these transformations are permanent. If Accord can demonstrate that patients can stay well and stay off (or on lower doses of) medications, it will provide the "evidence-based" ammunition needed to challenge the current drug-centered model of psychiatry.
As the $600,000 grant charts the progress of these first cohorts, the medical community will be watching. If successful, the house in Arlington may not just be a clinic, but the birthplace of a new standard in mental health care—one that prioritizes the body’s energy over the pharmacy’s chemistry.
